Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, William L. Dahut, Ravi A. Madan et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 312
The origin and dynamics of cellular heterogeneity vary across lineage subtypes of castrate resistant prostate cancerMichael L. Beshiri, Kathleen Kelly|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 3